| Budget Amount *help |
¥17,160,000 (Direct Cost: ¥13,200,000、Indirect Cost: ¥3,960,000)
Fiscal Year 2020: ¥3,510,000 (Direct Cost: ¥2,700,000、Indirect Cost: ¥810,000)
Fiscal Year 2019: ¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2018: ¥3,640,000 (Direct Cost: ¥2,800,000、Indirect Cost: ¥840,000)
Fiscal Year 2017: ¥6,110,000 (Direct Cost: ¥4,700,000、Indirect Cost: ¥1,410,000)
|
|---|
| Outline of Final Research Achievements |
Boron neutron capture therapy (BNCT) has been approved in Japan in March 2020 as the world's first treatment for head and neck tumors by combining the boron agent BPA with an accelerator neutron source. In this study, we focused on human serum albumin (HSA) as a boron carrier to apply BNCT to patients with BPA-insensitive cancers.
In order to achieve high boron accumulation in tumors, we focused on integrins, which are highly expressed on the surface of many tumor cells, and developed boronated albumin cRGD-HSA-MID with tumor targeting function. cRGD-HSA-MID showed high accumulation against human brain tumor U87MG cells, which are BPA-insensitive and high integrin expressing cells, and high BNCT anti-tumor effect was observed in the U87MG brain tumor Xenograft model.
|
